Back to stock research

Verified earnings summary

Research updated: Jul 12, 2026, 12:00 AM UTC

AMGN Q1 2026

Amgen reported first-quarter revenue of $8.6 billion, GAAP EPS of $3.34 and non-GAAP EPS of $5.15, with 16 brands growing at double-digit rates and multiple molecules advancing in Phase 3 development.

This page provides a source-verified release summary. It does not display a normalized metric table or post-earnings market reaction until those fields are independently verified.

Constructive signals after the release

  • Broad volume growth across Repatha, EVENITY, rare-disease and oncology products can offset declines in mature brands.
  • MariTide and other Phase 3 programs can create new growth franchises if clinical and regulatory milestones succeed.
  • Expansion of UPLIZNA, IMDELLTRA and other newer medicines can diversify product growth.

Risks that still need monitoring

  • Biosimilar erosion

    Competition is accelerating declines in Prolia, XGEVA and other established products.

  • Pricing and reimbursement

    Medicare price setting, 340B mix, payer pressure and global reforms can reduce net selling prices.

  • Pipeline and balance-sheet risk

    Clinical failures can impair growth expectations while acquisition-related debt and commitments limit flexibility.

Primary sources

Amgen Reports First Quarter 2026 Financial ResultsAmgen Inc. · earningsVerified

Fetched: 7/12/2026, 12:00:00 AM UTC

Published: 4/30/2026, 12:00:00 AM

Open original source
Amgen Inc. Investor RelationsAmgen Inc. · companyVerified

Fetched: 7/12/2026, 12:00:00 AM UTC

Open original source
Form 10-Q for the Quarter Ended March 31, 2026Amgen Inc. · filingVerified

Fetched: 7/12/2026, 12:00:00 AM UTC

Published: 4/30/2026, 12:00:00 AM

Open original source

Continue research

Open risk researchReturn to full stock research